SAGE Therapeutics Reports Fourth Quarter and Full Year 2014 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
SAGE Therapeutics (SAGE) Posts Q4 Loss of ~$1.57/Share
February 27, 2015 6:31 AM ESTSAGE Therapeutics (NASDAQ: SAGE) reported Q4 EPS of about ($1.57), $1.13 worse than the analyst estimate of ($0.44).
For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.
... More